

UNITED STATES PATENT AND TRADEMARK OFFICE

---

BEFORE THE PATENT TRIAL AND APPEAL BOARD

---

MYLAN PHARMACEUTICALS INC.,  
TEVA PHARMACEUTICALS USA, INC. and AKORN INC.,<sup>1</sup>  
Petitioners,

v.

SAINT REGIS MOHAWK TRIBE and ALLERGAN, INC.,  
Patent Owners.

---

Case IPR2016-01127 (8,685,930 B2)

Case IPR2016-01128 (8,629,111 B2)

Case IPR2016-01129 (8,642,556 B2)

Case IPR2016-01130 (8,633,162 B2)

Case IPR2016-01131 (8,648,048 B2)

Case IPR2016-01132 (9,248,191 B2)

---

**PETITIONER MYLAN PHARMACEUTICALS INC.'S  
MANDATORY CHANGE-OF-INFORMATION NOTICES**

---

<sup>1</sup> Cases IPR2017-00576 and IPR2017-00594, IPR2017-00578 and IPR2017-00596, IPR2017-00579 and IPR2017-00598, IPR2017-00583 and IPR2017-00599, IPR2017-00585 and IPR2017-00600, and IPR2017-00586 and IPR2017-00601, have respectively been joined with the captioned proceedings. The word-for-word identical paper is filed in each proceeding identified in the caption pursuant to the Board's Scheduling Order (Paper 10).

Pursuant to 37 C.F.R. § 42.8(a)(3), the undersigned on behalf of and acting in a representative capacity for Petitioner Mylan Pharmaceuticals Inc. (“Mylan”), hereby submits the following mandatory change-of-information notices in connection with the *inter partes* reviews identified in the caption.

**A. Real Party-In-Interest (37 C.F.R. § 42.8(b)(1)) – Unchanged**

**B. Related Matters (37 C.F.R. § 42.8(b)(2)) – Revised**

*Allergan, Inc. v. Teva Pharm. USA, Inc.*, No. 2018-1130 (Fed. Cir.)  
(mandate issued March 13, 2019; petition for certiorari denied June 3, 2019 (18-1289)) (**updated**)

*Allergan, Inc. v. Deva Holding A.S.*, No. 2:16-cv-1447 (E.D. Tex.) (final judgment entered April 30, 2019 based on Fed. Cir. Mandate in No. 2018-1130);

*Allergan, Inc. v. Saptalis Pharmaceuticals, LLC*, No. 1:18-cv-01231 (D. Del.) (suit asserting ’162 and ’556 patents voluntarily dismissed January 3, 2019);

*Allergan, Inc. v. Amneal Pharmaceuticals LLC*, No. 1:18-cv-01457 (D. Del.) (suit asserting ’162 and ’556 patents voluntarily dismissed January 3, 2019);

*St. Regis Mohawk Tribe v. Mylan Pharmaceuticals Inc.*, No. 2018-1638 (Fed. Cir.) (mandate issued November 20, 2018);

*St. Regis Mohawk Tribe v. Mylan Pharmaceuticals Inc.*, No. 18-899 (U.S.) (petition for certiorari denied April 15, 2019); and

U.S. Patent Application No. 15/585,320 (final rejection entered April 3, 2019).

**C. Lead and Back-up Counsel (37 C.F.R. § 42.8(b)(3)) – Unchanged**

**D. Electronic Service – Unchanged**

Respectfully submitted,

Dated: June 7, 2019

/ Steven W. Parmelee /

Steven W. Parmelee

Reg. No. 31,990

## CERTIFICATE OF SERVICE

This is to certify that I caused to be served a true and correct copy of the foregoing Petitioner Mylan Pharmaceuticals Inc.'s Mandatory Change-of-Information Notices on this 7<sup>th</sup> day of June, 2019, on the Patent Owner at the correspondence address of Allergan, Inc. and St. Regis Mohawk Tribe as follows:

Dorothy P. Whelan  
Michael Kane  
Susan Morrison Colletti  
Robert M. Oakes  
Jonathan Singer  
FISH & RICHARDSON P.C.  
3200 RBC Plaza  
60 South Sixth Street  
Minneapolis, MN 55402  
Email: [IPR13351-0008IP1@fr.com](mailto:IPR13351-0008IP1@fr.com)  
Email: [IPR13351-0008IP2@fr.com](mailto:IPR13351-0008IP2@fr.com)  
Email: [IPR13351-0008IP3@fr.com](mailto:IPR13351-0008IP3@fr.com)  
Email: [IPR13351-0008IP4@fr.com](mailto:IPR13351-0008IP4@fr.com)  
Email: [IPR13351-0008IP5@fr.com](mailto:IPR13351-0008IP5@fr.com)  
Email: [IPR13351-0008IP6@fr.com](mailto:IPR13351-0008IP6@fr.com)  
Email: [PTABInbound@fr.com](mailto:PTABInbound@fr.com)

Alfonso Chan  
Joseph DePumpo  
Michael W. Shore  
Christopher L. Evans  
SHORE CHAN DEPUMPO LLP  
901 Main Street, Suite 3300  
Dallas, TX 75201  
Email: [achan@shorechan.com](mailto:achan@shorechan.com)  
Email: [jdepumpo@shorechan.com](mailto:jdepumpo@shorechan.com)  
Email: [mshore@shorechan.com](mailto:mshore@shorechan.com)  
Email: [cevans@shorechan.com](mailto:cevans@shorechan.com)

Marsha K. Schmidt  
Email: [marsha@mkschmidtlaw.com](mailto:marsha@mkschmidtlaw.com)

And on the remaining petitioners as follows:

Gary Speier  
Mark Schuman  
CARLSON, CASPERS, VANDENBURGH,  
LINDQUIST & SCHUMAN, P.A.  
225 South Sixth Street, Suite 4200  
Minneapolis, MN 55402  
Email: [gspeier@carlsoncaspers.com](mailto:gspeier@carlsoncaspers.com)  
Email: [mschuman@carlsoncaspers.com](mailto:mschuman@carlsoncaspers.com)  
Email: [IPRCyclosporine@carlsoncaspers.com](mailto:IPRCyclosporine@carlsoncaspers.com)

Ralph Wilson Powers III  
STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.  
1100 New York Avenue, N.W.  
Washington, D.C. 20005  
Email: [tpowers-PTAB@sternekessler.com](mailto:tpowers-PTAB@sternekessler.com)  
Email: [PTAB@sternekessler.com](mailto:PTAB@sternekessler.com)  
*Attorneys for Teva Pharmaceuticals USA, Inc.*

Michael Dzwonczyk  
Mark Boland  
SUGHRUE MION, PLLC  
2100 Pennsylvania Ave., NW  
Washington, DC 20037  
Email: [mdzwonczyk@sughrue.com](mailto:mdzwonczyk@sughrue.com)  
Email: [mboland@sughrue.com](mailto:mboland@sughrue.com)  
*Attorneys for Akorn Inc.*

Respectfully submitted,

Dated: June 7, 2019

/ Steven W. Parmelee /  
Steven W. Parmelee, Lead Counsel  
Reg. No. 31,990